Loading
Life sciences · Journal article
British Journal of Cancer · August 8, 2026
Encouraging direction, but not yet definitive.
This retrospective analysis of 15,765 lung adenocarcinomas identifies high PDLIM2 expression as a prognostic biomarker associated with improved survival (24.1 vs 18.1 months, HR 0.84, multivariate HR 0.88, 95% CI 0.83–0.93), enhanced immune infiltration, and PD-L1 positivity. Preclinically, PDLIM2 gene therapy combined with chemoimmunotherapy improved survival in two syngeneic mouse models, but clinical efficacy remains untested and the authors acknowledge that PDLIM2's predictive (treatment-selection) role requires further evaluation.
Retrospective cohort analysis with preclinical syngeneic mouse model validation. 15,765 lung adenocarcinoma patients undergoing NGS and PD-L1 IHC; preclinical study used syngeneic mouse LUAD models. Intervention: High PDLIM2 expression (prognostic analysis); nano-complexed plasmid DNA-delivered PDLIM2 gene therapy, alone or with chemoimmunotherapy (preclinical). Compared with: Low PDLIM2 expression (prognostic analysis); chemoimmunotherapy alone (preclinical). n = 15,765.
PDLIM2-high tumors more common in primary/local versus metastatic biopsies (73.1% vs 53.0%; p < 0.001) High PDLIM2 associated with improved overall survival (24.1 vs 18.1 months; p < 0.001, HR 0.84) and remained prognostic in multivariate analysis (HR 0.88, 95% CI 0.83–0.93) High PDLIM2 linked to longer pembrolizumab time especially with platinum-based therapy (p = 0.012, HR 0.867)
Source does not report absolute survival rates, disease progression endpoints, or adverse event data for gene therapy
Clinicians should view PDLIM2 as a potential prognostic marker in LUAD that identifies immune-receptive tumors likely to benefit from immunotherapy; however, the therapeutic role of PDLIM2-based gene therapy remains preclinical, and no clinical trials have been reported. The authors appropriately caution that PDLIM2's predictive value for treatment selection requires prospective validation.
A real finding from a sound but limited study: PDLIM2 shows prognostic value in a large retrospective cohort and preclinical efficacy in mouse models, but lacks clinical trial data and the therapeutic benefit remains unvalidated in humans.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should view PDLIM2 as a potential prognostic marker in LUAD that identifies immune-receptive tumors likely to benefit from immunotherapy; however, the therapeutic role of PDLIM2-based gene therapy remains preclinical, and no clinical trials have been reported. The authors appropriately caution that PDLIM2's predictive value for treatment selection requires prospective validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background While PDZ-LIM domain-containing protein (PDLIM2) suppresses lung cancer, its clinical significance and therapeutic potential remain to be fully explored. Methods Next-generation sequencing and immunohistochemistry of programmed death ligand 1 (PD-L1) were performed on lung adenocarcinoma (LUAD) tissues from 15,765 patients. PDLIM2 gene therapy was tested in syngeneic LUAD mouse models using intravenous nano-complexed plasmid DNA, alone or with chemoimmunotherapy. Results PDLIM2 -high tumors were more common in primary/local biopsies versus metastatic samples (73.1% vs 53.0%; p < 0.001). High PDLIM2 expression was linked to lower mutation rates in RB1, TP53, SMARCA4, STK11, and KEAP1, but increased EGFR mutations (all p < 0.01). PDLIM2 -high tumors also showed increased immune cell infiltration, T cell-inflamed scores, and PD-L1 positivity (all p < 0.008). High PDLIM2 was associated with improved survival (24.1 vs 18.1 months; p < 0.001, HR = 0.84) and remained prognostic in multivariate analysis (HR = 0.88, 95% CI 0.83–0.93), as well as with longer pembrolizumab time, especially with platinum-based therapy ( p = 0.012, HR = 0.867). In two LUAD mouse models, nanoPDLIM2 improved median overall survival versus chemoimmunotherapy alone (10–12.5 vs 8–9 days; N = 8; p = 0.0001, 0.0003). Conclusion PDLIM2 is a promising prognostic biomarker in LUAD linked to immune-receptive tumors. Preclinically, PDLIM2 -based therapy enhances chemoimmunotherapy efficacy, though its predictive role warrants further evaluation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.